Pfizer (NYSE:PFE) Stock Price Down 1.3% – Should You Sell?

Pfizer Inc. (NYSE:PFE)’s share price dropped 1.3% on Tuesday . The company traded as low as $24.83 and last traded at $24.8850. Approximately 43,181,467 shares were traded during mid-day trading, a decline of 16% from the average daily volume of 51,487,402 shares. The stock had previously closed at $25.21.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on PFE shares. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. UBS Group reissued a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Scotiabank started coverage on Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 target price on the stock. Bank of America decreased their price target on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a report on Monday, December 15th. Finally, Morgan Stanley dropped their price objective on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $28.06.

Pfizer Trading Down 1.3%

The stock has a market capitalization of $141.49 billion, a PE ratio of 14.47 and a beta of 0.46. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The firm has a 50-day moving average price of $25.11 and a 200-day moving average price of $24.86.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The company had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

Hedge Funds Weigh In On Pfizer

Several institutional investors and hedge funds have recently bought and sold shares of the company. GKV Capital Management Co. Inc. purchased a new stake in Pfizer in the 1st quarter worth about $27,000. Curio Wealth LLC boosted its position in Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,098 shares during the period. Bayforest Capital Ltd purchased a new position in shares of Pfizer in the first quarter worth about $28,000. Grey Fox Wealth Advisors LLC bought a new stake in shares of Pfizer in the third quarter valued at approximately $29,000. Finally, Harbor Asset Planning Inc. purchased a new stake in shares of Pfizer during the 2nd quarter valued at approximately $29,000. 68.36% of the stock is owned by institutional investors.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.